Cargando…

CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain

The CD47/signal regulatory protein α pathway is an emerging immune checkpoint that is a new therapeutic target. We investigated CD47 expression in diffuse large B-cell lymphoma (DLBCL) of various subtypes and organs. Moreover, the relationship between CD47 expression and genetic alterations was anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Junhun, Yoon, Sang Eun, Kim, Seok Jin, Ko, Young Hyeh, Kim, Won Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768246/ https://www.ncbi.nlm.nih.gov/pubmed/35475881 http://dx.doi.org/10.1182/bloodadvances.2021006305

Ejemplares similares

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Metabolic activity of extranodal NK/T cell lymphoma on (18)F-FDG PET/CT according to immune subtyping
por: Lim, Chae Hong, et al.
Publicado: (2021)

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
por: Batlle-López, Ana, et al.
Publicado: (2016)

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
por: Cho, Junhun, et al.
Publicado: (2021)

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas
por: van der Meeren, L. E., et al.
Publicado: (2019)

Real-World Data Analysis of Survival Outcomes and Central Nervous System Relapses in Testicular Diffuse Large B Cell Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2023)

Comparison of the algorithms classifying the ABC and GCB subtypes in diffuse large B-cell lymphoma
por: Boltežar, Lučka, et al.
Publicado: (2018)

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma
por: Lee, Ji Yun, et al.
Publicado: (2021)

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma
por: Hough, R E, et al.
Publicado: (2001)

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma
por: Kang, Jin Hyun, et al.
Publicado: (2021)

Differences in mutational signature of diffuse large B‐cell lymphomas according to the primary organ
por: Koh, Hyun‐Hee, et al.
Publicado: (2023)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2016)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
por: Xu, Xin, et al.
Publicado: (2021)

Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis
por: Tsygankova, Svetlana, et al.
Publicado: (2022)

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism
por: Lim, Sung Hee, et al.
Publicado: (2016)

Loss of chromosome 11q21–23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
por: Stokke, T, et al.
Publicado: (2001)

Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997–2016: An observational study
por: Sim, Jongmin, et al.
Publicado: (2019)

Identification of BLNK and BTK as mediators of rituximab‐induced programmed cell death by CRISPR screens in GCB‐subtype diffuse large B‐cell lymphoma
por: Thomsen, Emil Aagaard, et al.
Publicado: (2020)

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab–CHOP
por: Hong, Jung Yong, et al.
Publicado: (2017)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma
por: Ryu, Kyung Ju, et al.
Publicado: (2020)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
por: Kim, Seok Jin, et al.
Publicado: (2023)

Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2022)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
por: Yoon, Nara, et al.
Publicado: (2017)

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months
por: Yoon, Sang Eun, et al.
Publicado: (2021)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers
por: Jernvall, P, et al.
Publicado: (1999)

Erratum to: The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
por: Kim, Seok Jin, et al.
Publicado: (2015)

Clonal relationships in recurrent B-cell lymphomas
por: Lee, Seung Eun, et al.
Publicado: (2016)

IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma
por: Jeong, Sun Young, et al.
Publicado: (2023)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
por: Lee, Hansang, et al.
Publicado: (2019)

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
por: Ma, Jiao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_50u474giqcdjh5o1pd9c98tseb